Vatreptacog Alfa from Conception to Clinical Proof of Concept

Egon Persson; Ole H. Olsen; Søren E. Bjørn; Mirella Ezban

doi:10.1055/s-0032-1302442

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2012; 38(03): 274-281
DOI: 10.1055/s-0032-1302442

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Vatreptacog Alfa from Conception to Clinical Proof of Concept

Egon Persson

¹Haemostasis Biology, Novo Nordisk A/S, Måløv, Denmark

,

Ole H. Olsen

¹Haemostasis Biology, Novo Nordisk A/S, Måløv, Denmark

,

Søren E. Bjørn

¹Haemostasis Biology, Novo Nordisk A/S, Måløv, Denmark

,

Mirella Ezban

¹Haemostasis Biology, Novo Nordisk A/S, Måløv, Denmark

› Author Affiliations

Abstract

Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement of the intrinsic (tissue factor-independent) capability to activate factor X and the downstream hemostatic events are consequently augmented. The beneficial effects of vatreptacog alfa have been demonstrated in numerous in vitro systems attempting to mimic hemophilia and corroborated in in vivo models. Vatreptacog alfa has successfully passed through phase 1 and 2 clinical trials and the molecule is currently being explored in phase 3 clinical trial for the treatment of bleedings in hemophilia patients with inhibitors. This article describes the proposed mechanism behind the increased activity and action of vatreptacog alfa and reviews available data, which suggest that vatreptacog alfa could be a valuable addition to the existing portfolio of treatment options for hemophilia patients with inhibitors.

Keywords

vatreptacog alfa - factor VIIa variant - intrinsic activity - factor X activation - tissue factor-independent capability

Full Text

References

References
1 Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost 2003; 29 (1) 77-86
2 Higashi S, Nishimura H, Aita K, Iwanaga S. Identification of regions of bovine factor VII essential for binding to tissue factor. J Biol Chem 1994; 269 (29) 18891-18898
3 Ruf W, Dickinson CD. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 1998; 8 (8) 350-356
4 Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 5 (6) 1097-1105
5 Olsen OH, Persson E. Cofactor-induced and mutational activity enhancement of coagulation factor VIIa. Cell Mol Life Sci 2008; 65 (6) 953-963
6 Pedersen AH, Nordfang O, Norris F , et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265 (28) 16786-16793
7 Higashi S, Nishimura H, Fujii S, Takada K, Iwanaga S. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate. J Biol Chem 1992; 267 (25) 17990-17996
8 Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2011; 17 (1) 11-16
9 Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 2001; 98 (24) 13583-13588
10 Pike ACW, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci U S A 1999; 96 (16) 8925-8930
11 Banner DW, D'Arcy A, Chène C , et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380 (6569) 41-46
12 Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol 2004; 41 (1, Suppl 1) 89-92
13 Fehlhammer H, Bode W, Huber R. Crystal structure of bovine trypsinogen at 1-8 A resolution. II. Crystallographic refinement, refined crystal structure and comparison with bovine trypsin. J Mol Biol 1977; 111 (4) 415-438
14 Petrovan RJ, Ruf W. Role of zymogenicity-determining residues of coagulation factor VII/VIIa in cofactor interaction and macromolecular substrate recognition. Biochemistry 2002; 41 (30) 9302-9309
15 Margaritis P, Roy E, Faella A , et al. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo. Blood 2011; 117 (15) 3974-3982
16 Petrovan RJ, Ruf W. Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem 2001; 276 (9) 6616-6620
17 Persson E, Olsen OH. Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. Eur J Biochem 2002; 269 (23) 5950-5955
18 Bjelke JR, Olsen OH, Fodje M , et al. Mechanism of the Ca2 + -induced enhancement of the intrinsic factor VIIa activity. J Biol Chem 2008; 283 (38) 25863-25870
19 Rand KD, Andersen MD, Olsen OH , et al. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. J Biol Chem 2008; 283 (19) 13378-13387
20 Sommer C, Norbert Jørgensen P, Salanti Z, Clausen JT, Jensen LB. Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats. Thromb Haemost 2007; 98 (4) 721-725
21 Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LVM. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5 (2) 336-346
22 Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27 (3) 683-689
23 He S, Ezban M, Bark N, Persson E, Hedner U. Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia. Thromb Haemost 2009; 102 (4) 790-792
24 Gray LD, Hussey MA, Larson BM , et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res 2011; 128 (6) 570-576
25 Lisman T, Mosnier LO, Lambert T , et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99 (1) 175-179
26 Lisman T, de Groot PG, Lambert T, Røjkjaer R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 1 (10) 2175-2178
27 Rea CJ, Foley J, Ezban M, Bevan D, Sorensen B. rFVIIa analogue and rFVIIa enhance clot stability more than FVIII in haemophilia A. J Thromb Haemost 2011; 9 (Suppl. 02) P-TU-503 (abstract)
28 Aljamali MN, Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Haemophilia 2009; 15 (6) 1318-1326
29 Sørensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137 (2) 158-165
30 Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr Jr ME. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13 (5) 533-541
31 Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagul Fibrinolysis 2010; 21 (6) 539-546
32 Brophy DF, Martin EJ, Barrett JC , et al. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul Fibrinolysis 2011; 22 (6) 541-546
33 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99 (3) 542-547
34 Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5 (4) 774-780
35 Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost 2011; 9 (4) 759-766
36 Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIa—from molecular to clinical aspects of a versatile haemostatic agent. Thromb Res 2010; 125 (6) 483-489
37 Tranholm M, Kristensen K, Kristensen AT, Pyke C, Røjkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102 (10) 3615-3620
38 Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7 (9) 1517-1522
39 Øvlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost 2008; 6 (6) 969-975
40 Whinna HC, Monroe DM. A novel murine hemostasis model: studies on recombinant factor VIIa and NN1731. J Thromb Haemost 2009; 7 (Suppl. 02) PP-MO-392 (abstract)
41 Lauritzen B, Hedner U, Johansen PB, Tranholm M, Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost 2008; 6 (5) 804-811
42 Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7 (4) 651-657
43 Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108 (9) 3053-3060
44 McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007; 5 (8) 1577-1583
45 Hoffman M, Brock J, Ezban M, Monroe DM. An analogue of factor VIIa improves wound healing in hemophilia B mice. J Thromb Haemost 2011; 9 (Suppl. 02) P-MO-550 (abstract)
46 Agersø H, Brophy DF, Pelzer H , et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011; 9 (2) 333-338
47 Petersen LC, Karpf DM, Agersø H , et al. Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. Br J Haematol 2011; 152 (1) 99-107
48 Agersø H, Kristensen NR, Østergaard H , et al. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs. Eur J Pharm Sci 2011; 42 (5) 578-583
49 Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009; 7 (2) 299-305
50 Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16 (4) 259-266
51 De Paula E, Kavakli K, Mahlangu J , et al, on behalf of 1804 (adept™ 1) Investigators. Clinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors. J Thromb Haemost 2012; 10 (1) 81-89